FORM 12B-25 NOTIFICATION OF LATE FILING
SEC FILE NUMBER
CUSIP NUMBER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Check One): x Form 10-K Form 20-F Form 11-K Form 10-Q Form N-SAR
For Period Ended: December 31, 1998
Transition Report on Form 10-K
Transition Report on Form 20-F Transition Report on Form 11-K
Transition Report on Form 10-A Transition Report on Form N-SAR
For the Transition Period Ended:
Read Instruction (on back page) Before Preparing Form, Please
Print or Type.
Nothing in this form shall be construed to imply that the
Commissions have verified any information contained herein.
If the notification relates to a portion of the filing checked
above, identify the item(s) to which the notification relates:
PART I - REGISTRATION INFORMATION (Official Text)
Full Name of Registrant: IGENE Biotechnology, Inc.
Former Name if Applicable:
Address of Principal Executive
Office (Street and Number): 9110 Red Branch Road
City, State and Zip Code: Columbia, Maryland 21045-2024
PART II - RULES 1b-25(b) AND (c) (Official Text)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to
Rule 12b-25(b), the following should be completed. (Check box if
appropriate) x
(a) The reasons described in reasonable detail in Part III of
this form could not be eliminated without unreasonable
effort or expense;
(b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K, form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject
quarterly report of transition report on Form 10-Q, or
portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III - NARRATIVE (Official Text)
State below in reasonable detail the reasons why the Form 10-K,
11-K, 10-Q, N-SAR, or the transition report or portion thereof,
could not be filed within the prescribed time period. (Attach
Extra Sheets if Needed)
PART IV - OTHER INFORMATION (Official Text)
(1) Name and telephone number of person to contact in regard to
this notification
Stephen F. Hiu
410-997-2599
(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 of Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or
for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
YES
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal
year will be reflected by the earnings statement to be
included in the subject report or portion thereof?
NO
If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the
reasons why a reasonable estimate of the results cannot be made.
Name of Registrant as Specified in Charter:
IGENE Biotechnology, Inc. has caused this notification to be
signed on its behalf by the undersigned hereunto duly authorized.
Date: March 16, 1999
By: /s/ Stephen F. Hiu, Ph.D., President
INSTRUCTIONS:
The form may be signed by an executive officer of the registrant
or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed
beneath the signature. If the statement is signed on behalf of
the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements of omissions of fact constitute Federal
Criminal Violations (See 18 U.S.C. 1001).
GENERAL INSTRUCTIONS (Official Text)
1. This form is required by Rule 12b-25 (17 CFR 240.12b-25) of
the General Rules and Regulations under the Securities
Exchange Act of 1934.
2. One signed original and four conformed copies of this form
and amendments thereto must be completed and filed with the
Securities and Exchange Commission, Washington, D.C. 20549,
in accordance with Rule 0-3 of the General Rules and
Regulations under the Act. The information contained in or
filed with the form will be made a matter of public record
in the Commission files.
3. A manually signed copy of the form and amendments thereto
shall be filed with each national securities exchange on
which any class of securities of the registrant is
registered.
4. Amendment to the notification must also be filed on Form 12b-
25 but need not restate information that has been correctly
furnished. The form shall be clearly identified as an amendment
notification.
5. Electronic Filers. This form shall not be used by
electronic filers unable to timely file a report solely due
to electronic difficulties. Filers unable to submit a report
within the time period prescribed due to difficulties in
electronic filing should comply with either Rule 201 or Rule
202 of Regulation S-T (232.201 or 232.202 of this chapter)
or apply for an adjustment in filing date pursuant to Rule
13(b) of Regulation S-T (232.13(b) of this chapter).
(Amended by Sec Act Rel No. 7122, Esch Act Rel No. 35113,
eff 1/30/95).
<PAGE>
March 11, 1999
Berenson & Company LLC
Certified Public Accounts and Consultants
135 West 50th
StreetNew York, NY 10020
212-977-6800
FAX: 212-245-3808 or 212-245-7098
http://www.berenson.com
email: [email protected]
1912 Sunderland Place, NW
Washington, DC 20036
202-331-1044
FAX: 202-331-1085
United States Security and
Exchange Commission
Washington, D.C. 20549
Re: Igene Biotechnology, Inc.
EIN: 52-1230461
To Whom It May Concern:
We are the independent auditors for Igene Biotechnology, Inc. We
are unable at this point in time to express an opinion on the
Company's December 31, 1998 financial statements or review the 10
KSB as Igene is awaiting the outcome of significant subsequent
events which could impact the financial statement disclosures.
Respectfully yours,
/s/ Berenson & Company LLP
